An update on the phase III Zeus trial with ziltivekimab nicked shares of Novo Nordisk A/S (NYSE:NVO), which were trading at $47.20, down $4.38. Low coffers, failed endometrial cancer trial: Karyopharm down 70%Quickly running out of cash, Karyopharm Therapeutics Inc. found itself in a precarious situation July 30 when top-line phase III results showed Xpovio (selinexor) failed to meet the progression-free survival (PFS) primary endpoint in endometrial cancer (EC). Reporting its second quarter results, Mimedx saw sales for its wound segment drop 61% year-over-year and its total revenue down 35%. Another $24 million could come if underwriters exercise their overallotment option for an additional 1.5 million shares. Definium Therapeutics Inc.’s LSD-based DT-120 delivered a phase III win in major depressive disorder, with shares surging 49.8% on data showing rapid, durable antidepressant effects.